Literature DB >> 29242354

Moving Synergistically Acting Drug Combinations to the Clinic by Comparing Sequential versus Simultaneous Drug Administrations.

Saketh S Dinavahi1, Mohammad A Noory1, Raghavendra Gowda1, Joseph J Drabick1, Arthur Berg1, Rogerio I Neves1, Gavin P Robertson2.   

Abstract

Drug combinations acting synergistically to kill cancer cells have become increasingly important in melanoma as an approach to manage the recurrent resistant disease. Protein kinase B (AKT) is a major target in this disease but its inhibitors are not effective clinically, which is a major concern. Targeting AKT in combination with WEE1 (mitotic inhibitor kinase) seems to have potential to make AKT-based therapeutics effective clinically. Since agents targeting AKT and WEE1 have been tested individually in the clinic, the quickest way to move the drug combination to patients would be to combine these agents sequentially, enabling the use of existing phase I clinical trial toxicity data. Therefore, a rapid preclinical approach is needed to evaluate whether simultaneous or sequential drug treatment has maximal therapeutic efficacy, which is based on a mechanistic rationale. To develop this approach, melanoma cell lines were treated with AKT inhibitor AZD5363 [4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide] and WEE1 inhibitor AZD1775 [2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one] using simultaneous and sequential dosing schedules. Simultaneous treatment synergistically reduced melanoma cell survival and tumor growth. In contrast, sequential treatment was antagonistic and had a minimal tumor inhibitory effect compared with individual agents. Mechanistically, simultaneous targeting of AKT and WEE1 enhanced deregulation of the cell cycle and DNA damage repair pathways by modulating transcription factors p53 and forkhead box M1, which was not observed with sequential treatment. Thus, this study identifies a rapid approach to assess the drug combinations with a mechanistic basis for selection, which suggests that combining AKT and WEE1 inhibitors is needed for maximal efficacy.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29242354      PMCID: PMC5801555          DOI: 10.1124/mol.117.110759

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  26 in total

1.  Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.

Authors:  Barry R Davies; Hannah Greenwood; Phillippa Dudley; Claire Crafter; De-Hua Yu; Jingchuan Zhang; Jing Li; Beirong Gao; Qunsheng Ji; Juliana Maynard; Sally-Ann Ricketts; Darren Cross; Sabina Cosulich; Christine C Chresta; Ken Page; James Yates; Clare Lane; Rebecca Watson; Richard Luke; Donald Ogilvie; Martin Pass
Journal:  Mol Cancer Ther       Date:  2012-01-31       Impact factor: 6.261

2.  Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

Authors:  Khanh Do; Deborah Wilsker; Jiuping Ji; Jennifer Zlott; Tomoko Freshwater; Robert J Kinders; Jerry Collins; Alice P Chen; James H Doroshow; Shivaani Kummar
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

3.  Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.

Authors:  Dongchun Wang; Zhenzhou Jiang; Luyong Zhang
Journal:  Med Oncol       Date:  2011-04-01       Impact factor: 3.064

4.  Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor.

Authors:  Andrea S Fung; Man Yu; Qian Jess Ye; Ian F Tannock
Journal:  Cancer Chemother Pharmacol       Date:  2013-07-14       Impact factor: 3.333

Review 5.  Combinatorial drug therapy for cancer in the post-genomic era.

Authors:  Bissan Al-Lazikani; Udai Banerji; Paul Workman
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

6.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

7.  Deregulated Akt3 activity promotes development of malignant melanoma.

Authors:  Jill M Stahl; Arati Sharma; Mitchell Cheung; Melissa Zimmerman; Jin Q Cheng; Marcus W Bosenberg; Mark Kester; Lakshman Sandirasegarane; Gavin P Robertson
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

8.  Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.

Authors:  SubbaRao V Madhunapantula; Arati Sharma; Raghavendra Gowda; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2013-09-19       Impact factor: 4.693

9.  Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.

Authors:  X Wang; L Zhang; A O'Neill; B Bahamon; D C Alsop; J W Mier; S N Goldberg; S Signoretti; M B Atkins; C G Wood; R S Bhatt
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

10.  A novel AKT3 mutation in melanoma tumours and cell lines.

Authors:  M A Davies; K Stemke-Hale; C Tellez; T L Calderone; W Deng; V G Prieto; A J F Lazar; J E Gershenwald; G B Mills
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

View more
  3 in total

1.  Targeting WEE1/AKT Restores p53-Dependent Natural Killer-Cell Activation to Induce Immune Checkpoint Blockade Responses in "Cold" Melanoma.

Authors:  Nicholas D Huntington; Gavin P Robertson; Saketh S Dinavahi; Yu-Chi Chen; Kishore Punnath; Arthur Berg; Meenhard Herlyn; Momeneh Foroutan
Journal:  Cancer Immunol Res       Date:  2022-06-03       Impact factor: 12.020

Review 2.  Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment.

Authors:  Luisa Maresca; Barbara Stecca; Laura Carrassa
Journal:  Cells       Date:  2022-04-26       Impact factor: 7.666

3.  Targeting Protein Translation in Melanoma by Inhibiting EEF-2 Kinase Regulates Cholesterol Metabolism though SREBP2 to Inhibit Tumour Development.

Authors:  Saketh S Dinavahi; Yu-Chi Chen; Raghavendra Gowda; Pavan Kumar Dhanyamraju; Kishore Punnath; Dhimant Desai; Arthur Berg; Scot R Kimball; Shantu Amin; Jin-Ming Yang; Gavin P Robertson
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.